tiprankstipranks
Biogen license application for lecanemab designated for priority review in China
The Fly

Biogen license application for lecanemab designated for priority review in China

Eisai (ESALY) and Biogen (BIIB) announced that the Biologics License Application for lecanemab, an investigational anti-amyloid beta protofibril antibody, has been designated for Priority Review by the National Medical Products Administration in China. The Priority Review and Approval Procedure was implemented by the NMPA with the aim of accelerating research, development and launch of new medicines that have significant clinical value. Under this Procedure, the assessment period is expected to be shortened. In China, Eisai initiated submission of data for the BLA to the NMPA in December 2022. Eisai initially submitted a package that includes data from the Phase II clinical trial and the top-line data of the large global Phase III Clarity AD study in mild cognitive impairment due to Alzheimer’s disease and mild AD with confirmed Abeta accumulation in the brain. Eisai will submit additional data including full data of the Clarity AD study, as directed by the NMPA.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on BIIB:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles